SCHEMBL20549665

SCHEMBL20549665

CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1)B1OCCN(CC(=O)NC(P(=O)(O)O)P(=O)(O)O)CCO1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMB5 P28074 18/20 0.56
▸ PSMB1 P20618 11/20 0.53
▸ PSMB8 P28062 10/20 0.53
▸ PSMB9 P28065 10/20 0.53
▸ PSMB6 P28072 10/20 0.53
▸ PSMB10 P40306 10/20 0.53
▸ PSMB2 P49721 10/20 0.53
▸ PSMB11 A5LHX3 9/20 0.53
▸ PSMA7 O14818 9/20 0.53
▸ PSMA1 P25786 9/20 0.53
▸ PSMA2 P25787 9/20 0.53
▸ PSMA3 P25788 9/20 0.53
▸ PSMA4 P25789 9/20 0.53
▸ PSMA5 P28066 9/20 0.53
▸ PSMB4 P28070 9/20 0.53
▸ PSMB3 P49720 9/20 0.53
▸ PSMA6 P60900 9/20 0.53
▸ PSMA8 Q8TAA3 9/20 0.53
▸ PSMB7 Q99436 9/20 0.53
▸ LONP1 P36776 8/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20549663 1.00 PSMB5 (0.56) PSMB5PSMB1PSMB8PSMB9PSMB6
SCHEMBL20549712 0.92 PSMB5 (0.55) PSMB5PSMB1PSMB8PSMB9PSMB6
SCHEMBL20549905 0.92 PSMB5 (0.55) PSMB5PSMB1PSMB8PSMB9PSMB6
SCHEMBL24637970 0.92 PSMB5 (0.55) PSMB5PSMB1PSMB8PSMB9PSMB6
SCHEMBL18848525 0.92 PSMB5 (0.55) PSMB5PSMB1PSMB8PSMB9PSMB6
SCHEMBL18848503 0.91 PSMB5 (0.55) PSMB5PSMB1PSMB8PSMB9PSMB6
SCHEMBL24637955 0.90 PSMB5 (0.54) PSMB5PSMB1PSMB8PSMB9PSMB6
SCHEMBL24637954 0.90 PSMB5 (0.54) PSMB5PSMB1PSMB8PSMB9PSMB6
SCHEMBL18848561 0.90 PSMB5 (0.54) PSMB5PSMB1PSMB8PSMB9PSMB6
SCHEMBL18848528 0.90 PSMB5 (0.54) PSMB5PSMB1PSMB8PSMB9PSMB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11497813-B2 Bortezomib conjugates and methods using same BIOVINC, LLC (US) 2022-11-15 — — US disclosed
EP-3371203-B1 BORTEZOMIB CONJUGATES AND METHODS USING SAME UNIV ROCHESTER (US) 2020-02-26 — — EP disclosed
US-20180318425-A1 Bortezomib Conjugates and Methods Using Same BIOVINC, LLC 2018-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11497813-B2 Bortezomib conjugates and methods using same BCR, PSMA6, PSMA5 PSMB5 15/4885PSMB1 69/4885PSMB8 253/4885
US-20180318425-A1 Bortezomib Conjugates and Methods Using Same BCR, PSMA6, PSMA5 PSMB5 15/4885PSMB1 69/4885PSMB8 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback